Key facts
- Nabla Bio’s last known valuation is $140.9M (May 2024).
- It has raised $37.0M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Y Combinator, US National Science Foundation, Khosla Ventures, Fifty Years, Pillar VC — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Nabla Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Nabla Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nabla Bio
Developer of Artificial Intelligence (AI) and wet-lab technologies designed for the rational designing of developable, selective, and functional drugs. The company offers integrated AI-driven modeling, high-throughput multiplex screening, and wet-lab validation, enabling pharmaceutical companies to create drugs against previously undruggable targets with enhanced precision and efficacy.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 20
- Website
- nabla.bio/
- Ownership
- Privately Held (backing)
Nabla Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nabla Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nabla Bio in its N-PORT filings yet. We sweep new filings monthly.